Table 3.
Expanded NK cell cytolytic activity
| Treated Subjects | Allo/ Auto | Recipient Missing KIR-L | Expanded NK
|
Specific Lysis (%)
|
||||
|---|---|---|---|---|---|---|---|---|
| CD3−56+ Potentially Alloreactive (%) | Potentially Alloreactive & licensed (%) | K562 | Donor NK vs. Recipient Myeloma | Donor NK vs. Unrelated Myeloma | Unrelated NK vs Recipient Myeloma | |||
|
|
|
|
|
|
|
|
|
|
| 1 | Auto | None | 0 | 0 | 81.1 | 8.3 | 30.9 | 19.0 |
| 2 | Allo | II, Bw4 | 17.4 | 13.2 | 84.4 | 45.7 | 19.0 | 50.1 |
| 3 | Auto | None | 0 | 0 | 78.2 | NA | 46.7 | NA |
| 4 | Auto | None | 0 | 0 | 71.1 | 8.2 | 58.7 | 18.0 |
| 5 | Allo | II | 33.4 | 33.4 | 71.2 | 74.3 | 49.5 | 63.1 |
| 6 | Auto | I | 27.1 | 0 | 77.0 | 5.4 | 51.0 | 49.9 |
| 7 | Auto | None | 0 | 0 | 81.7 | 45.0 | 28.5 | 58.7 |
| 8 | Allo | Bw4 | 12.5 | 0 | 80.4 | NA | 36.5 | NA |
Potentially alloreactive expanded NK cells were defined as CD3−56+ cells expressing KIR(s) recognizing the missing ligand(s) in the recipient and also negative for NKG2A and KIRs recognizing ligands present in the recipient. Licensed NK were defined as alloreactive NK derived from a donor expressing the KIR-L that was missing in the recipient. Allo, Allogeneic product recipients; Auto, Autologous product recipients; NA, Primary myeloma was not available from subjects 3 and 8.